T. Rowe Price Associates
Funding rounds backed by T. Rowe Price Associates.
- Funding disclosed in full
- $4.4B
- Median round
- $350M
- Rounds in calculation
- 9
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| Cyclic Materials Cyclic Materials recovers and produces rare earth materials through recycling. | $75MStrategic | Climate techCanada | |||
| Castelion Builds low-cost, mass-producible hypersonic strike missiles for defense | $1BSeries C | Defense techUnited States | |||
| Hadrian Builds highly automated factories producing defense and aerospace systems | $1.4BSeries D | Defense techUnited States | 16 participants137 Ventures1789 CapitalAltimeterAndreessen Horowitz (a16z)ApolloBaillie GiffordCapitalGConstruct CapitalFounders FundJPMorganChase Strategic Investment GroupLux CapitalMorgan Stanley Wealth ManagementT. Rowe Price AssociatesValor Equity PartnersWashington Harbour PartnersWCM Investment Management | ||
| K2 Space Manufacturer of big, high-power satellites | $500MSeries D | Space techUnited States | |||
| AdvanCell Develops lead-212 targeted alpha therapies to treat cancer | $315MSeries D | BiotechAustralia | 19 participantsAbingworthAlly Bridge GroupAlpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital | ||
| SambaNova Provides next-generation AI infrastructure for enterprises, neo-clouds, and sovereign AI initiatives | $350MSeries E | AIUnited States | |||
| Third Arc Bio Develops novel multifunctional antibodies for oncology and immunology & inflammation indications | $52MSeries A+ | BiotechUnited States | |||
| ClickHouse Provides real-time analytics, data warehousing, observability, and AI/ML infrastructure | $400MSeries D | Developer toolsUnited States | |||
| Hadrian Builds highly automated factories producing defense and aerospace systems | UndisclosedUndisclosed | Industrial techUnited States | |||
| Parabilis Medicines Develops medicines targeting historically undruggable protein targets in cancer | $305MSeries F | BiotechUnited States | 23 participantsAlderline GroupARCH Venture PartnersCatalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners |